A 52-Week Treatment, Multi-Center, Randomized, Open Label, Parallel Group Study to Assess the Long Term Safety and Efficacy of Indacaterol (300 microg o.d.) Using Salmeterol (50 microg b.i.d.) as an Active Control in Japanese Patients With Chronic Obstructive Pulmonary Disease(COPD).

Trial Profile

A 52-Week Treatment, Multi-Center, Randomized, Open Label, Parallel Group Study to Assess the Long Term Safety and Efficacy of Indacaterol (300 microg o.d.) Using Salmeterol (50 microg b.i.d.) as an Active Control in Japanese Patients With Chronic Obstructive Pulmonary Disease(COPD).

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Oct 2011

At a glance

  • Drugs Indacaterol; Salmeterol
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions; Registrational
  • Most Recent Events

    • 24 Nov 2010 Actual end date (Nov 2010) added as reported by ClinicalTrials.gov.
    • 24 Nov 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Oct 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top